Iron and molybdenum complexes supported by a pincer-type dianionic [NS2]2- donor were prepared to compare their structural, spectroscopic, and electrochemical properties. The versatility of the [NS2]2Mo(iv) complex (2) to access different oxidation states was evidenced in the activation of methanol and isopropanol, oxidising them to formaldehyde or acetone with concomitant reduction and protonation to afford [NHS2]2Mo(ii), complex (3). This redox behaviour contrasts with the null reactivity observed for the analogous ferric complex [NS2][NHS2]Fe(iii) (1). Complex 2 presents a quasi-reversible process at E1/2 = -0.80 V relative to the ferrocenium/ferrocene couple (Fc+/Fc), which is attributed to the Mo(iv)/Mo(v) redox couple. Two irreversible cathodic processes were observed at Ecp = -1.59 and -2.20 V, which are attributed to the Mo(iv)/Mo(iii) and Mo(iii)/Mo(ii) redox couples. Cyclic voltammetry and solid-state structures obtained by X-ray crystallography support a 2H+ and 2e- process, whereby the Mo(iv) centre in 2 is reduced sequentially to Mo(iii), and finally to Mo(ii) in 3. These redox events were observed at Ecp = -1.22 and -2.15 V (vs. Fc+/Fc) in the anodic cyclic voltammograms of 2 in THF in the presence of acid. A new reduction peak was detected under these conditions at Ecp = -2.30 V, consistent with electrocatalytic proton reduction. This was corroborated for 2 as a catalyst precursor in the presence of increasing amounts of p-toluenesulfonic acid, with the addition of 2 to 14 equivs resulting in an increase of the current measured.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1039/c8dt01562g | DOI Listing |
Transfusion
December 2024
Dipartimento di Scienze di Laboratorio ed Ematologiche, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.
Background: Extracorporeal photopheresis (ECP) has been demonstrated as an effective treatment for graft-versus-host disease (GvHD). The inline system was developed by Therakos in 1987. Recently, Fresenius Kabi implemented an integration of cell separator Amicus and a UVA photoactivation device (Phelix), realizing an inline photopheresis system.
View Article and Find Full Text PDFInt J Biol Macromol
December 2024
School of Bioengineering, Qilu University of Technology, Shandong Academy of Sciences, Jinan 250353, Shandong, PR China; State Key Laboratory of Bio-based Materials and Green Papermaking, Qilu University of Technology, Shandong Academy of Sciences, Jinan 250353, Shandong, PR China. Electronic address:
World Allergy Organ J
November 2024
Group of Clinical and Experimental Allergy (GACE), Hospital "Alma Mater de Antioquia", University of Antioquia, Medellín, Colombia.
Introduction: Atopic dermatitis (AD) is a frequent disease in infants with diverse clinical evolution. Although multiple studies have assessed inflammatory changes in chronic AD, little is known about the molecular transition from symptomatic stage to clinical remission without pharmacotherapy.
Objective: The aim of the study was to evaluate clinical and inflammatory factors and its relationship with AD clinical evolution.
Sci Rep
November 2024
Translational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven, Leuven, Belgium.
Eosinophils were previously reported to play a role in intestinal inflammation and fibrosis. Whether this is as a bystander or as an active participant is still up for debate. Moreover, data describing a causal relationship between eosinophils and intestinal fibrosis are scarce.
View Article and Find Full Text PDFBackground And Purpose: Levodopa-entacapone-carbidopa intestinal gel (LECIG) infusion is a recently developed device-aided therapy for advanced Parkinson disease (PD) patients. The aim of this study was to report real-world evidence about the effectiveness, tolerability, and safety of LECIG in PD patients.
Methods: A multicenter observational retrospective study of the first patients who initiated LECIG in Spain was performed.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!